Synthace CEO Tim Fell
The innovative biotech start-up has developed a language and software platform specifically for biology that lets researchers aim higher and achieve better results.
Synthace, the London-based technology start-up behind the Antha operating system for biology, has announced that it has raised £7.3m in Series A funding.
White Cloud Capital, Amadeus Capital Partners and Eleven Two Capital participated in the round alongside existing shareholders that included Sofinnova Partners, SOSV and Bioeconomy Capital.
Synthace CEO Tim Fell said: “A sustainable future simply must include a better ability to engineer biology.
“Our need to heal, feed, fuel and manufacture for a growing population can be met by unlocking the near infinite power of biology but only by bringing software abstraction and more automation to biological R&D and manufacturing, and by enabling biologists to build atop their collective work.
“That is what the Antha platform does, and why we are so passionate about realising its potential.”
Synthace will use the investment to expand the rapidly growing eco-system of biologists, lab instrumentation manufacturers, reagent and consumable suppliers, bio-design and analysis software developers and cloud providers adopting Antha as the connecting platform for biotechnology.
This is key to enabling interoperability in hardware, working practices, and data in the life sciences, and something taken for granted in many other industries.
Isabel Fox, head of venture at White Cloud Capital, added: “Synthace is transforming the way biotechnology is developed and the US$170bn global life science R&D budget spent.
“The traction the company has achieved with pharmaceutical, agritech and industrial biotechnology customers shows the cross-sector applicability of Antha.
“We are excited to support the company in bringing this technology to the immense market of any researcher or organisation developing products or services that incorporate biology.”